Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, have been published in Clinical Genitourinary Cancer.
The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
Discover more about how we help to shape the future of oncology treatments here.
Jump to a slide with the slide dots.
Ashfield MedComms Win at the 2025 Communiqué Awards
Ashfield MedComms, part of Inizio Medical, wins at the 2025 Communiqué Awards with AstraZeneca for the Rosetta-Lung Project, celebrating excellence in
Read moreThree years of Inizio: Reimagining health by uniting the talents of 10,500 experts
Three years ago, Inizio was born. Not as a newcomer, but as a bold reinvention.
Read moreBig ideas, smart spaces, and strategic insights from ASCO® 2025
Watch our webcast for an insider’s perspective on ASCO® 2025 - where innovation, investment, and impact converged.
Read more